Objective

Bicycle Therapeutics are pioneering the development of bicyclic peptides, or Bicycles® — a new class of versatile, chemically synthesised medicines. Bicycles address therapeutic needs unreachable with any other existing modality. Their small size and exquisite tumour targeting delivers rapid tumour penetration and retention while clearance rates and routes can be tuned to minimise exposure of healthy tissue and toxicities. Bicycle Toxin Conjugates link a potent toxin payload to a Bicycle designed to bind to a tumour surface antigen. This targeted approach rapidly delivers payloads into solid tumours, with extensive tissue penetration, a short duration of systemic exposure and liver-sparing rapid renal elimination. These properties limit the body’s exposure to toxin to control any damage to normal tissue.